
    
      The two doses of AVE5530 tested in this study are 25 mg and 50 mg taken in the evening, with
      dinner dosing. The study will include a pre-randomization phase up to 6 weeks, a double-blind
      treatment period of at least 12 months and can be variably extended up to approximately 18
      months.
    
  